Company news

Dogwood Therapeutics, Inc. news in 2024

Dogwood Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study

November 17, 2024

Dogwood Therapeutics Announces Third Quarter 2024 Financial Results

November 6, 2024

Dogwood Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Thursday, November 7, 2024

October 30, 2024

Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

October 29, 2024

Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)

October 6, 2024

Virios Therapeutics Announces Second Quarter 2024 Financial Results

August 7, 2024

Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

July 31, 2024

Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center

July 22, 2024

Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

May 21, 2024

Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

May 18, 2024

Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

May 16, 2024

Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024

Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

May 1, 2024

Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID

March 25, 2024

Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

February 28, 2024

Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones

February 27, 2024

Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID

January 21, 2024

Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID

January 1, 2024

Calls in 2024

Decks in 2024